3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives

Compounds of the formula I

• in which
• R1 denotes OH, OA, O[C(R5)2]nAr, O[C(R5)2]nHet, O[C(R5)2]pN(R5)2, N(R5)2, NR5[C(R5)2]nAr, NR5[C(R5)2]nHet, NR5[C(R5)2]pN(R5)2, COOR5, CON(R5)2, CONR5[C(R5)2]pN(R5)2, CONR5[C(R5)2]pOR5, CONR5[(R5)2]nHet, COHet or COA,
• R2 denotes H, A, Hal, OH, OA, N(R5)2, N═CR5N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2, S(O)mA, Het, [C(R5)2]nN(R5)2, [C(R5)2]nHet, O[C(R5)2]nN(R5)2, O[C(R5)2]nHet, S[C(R5)2]pN(R5)2, S[C(R5)2]nHet, NR5[C(R5)2]pN(R5)2, —NR5[C(R5)2]nHet, NHCON(R5)2, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]n-Het, NHCO[C(R5)2]pN(R5)2, NHCO[C(R5)2]nHet, CON(R5)2, CONR5[C(R5)2]pN(R5)2, CONR5[C(R5)2]nHet, COHet, COA, O[C(R5)2]nNR5COZ, O[C(R5)2]nNR2COHet1, O[C(R5)2]nCyc[C(R5)2]nN(R5)2, O[C(R5)2]nCyc[C(R5)2]nOR5, O[C(R5)2]nCyc[C(R5)2]nHet1,
• O[C(R5)2]nCR5(NR5)2COOR5, O[C(R5)2]nNR5CO[C(R5)2]nNR5COA, O[C(R5)2]nNR5COOA, O[C(R5)2]nCO—NR5-A, O[C(R5)2]nCO—NR5—[C(R5)2]nHet1, O[C(R5)2]nCONH2, O[C(R5)2]nCONHA, O[C(R2)2]nCONA2, O[C(R5)2]nCO—NR5—[C(R2)2]nN(R5)2 or OCOA,
• Z denotes CR5(NR5)2CR5(OR5)A,
• R3, R3′ each, independently of one another, denote H, F or A, together also denote alkylene having 2-5 C atoms,
• R4 denotes H, A or Hal,
• R5 denotes H or A′,
• A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br, and/or in which one or two CH2 groups may be replaced by O, NH, 5, SO, SO2 and/or CH═CH groups,
• or
• cyclic alkyl having 3-7 C atoms, in which 1-7 H atoms may be replaced by OH, F, Cl and/or Br,
• A′ denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F,
• Cyc denotes cycloalkylene having 3-7 C atoms,
• Ar denotes phenyl, naphthyl or biphenyl, each of which is un-substituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, SR5, NO2, CN, COORS, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2 and/or S(O)mA,
• Het denotes a mono-, bi- or tricyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OR5, N(R5)2, SR5, NO2, CN, COOR5, CON(R5)2, NR5COA, NR5SO2A, SO2N(R5)2, S(O)mA, CO-Het1, Het1, [C(R5)2]n—N(R5)2, [C(R5)2]nHet1, O[C(R5)2]pN(R5)2, O[C(R5)2]nHet1, NHCOOA, NHCON(R5)2, NHCOO[C(R5)2]pN(R5)2, NHCOO[C(R5)2]nHet1, NHCONH[C(R5)2]pN(R5)2, NHCONH[C(R5)2]nHet1, OCONH[C(R5)2]pN(R5)2, OCONH[C(R5)2]nHet1, CO-Het1, CHO, COA, ═S, —NH, ═NA and/or ═O (carbonyl oxygen),
• Het1 denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be mono- or disubstituted by A, OA, OH, Hal and/or ═O (carbonyl oxygen),
• Hal denotes F, Cl, Br or I,
• m denotes 0, 1 or 2,
• n denotes 0, 1, 2, 3 or 4,
• p denotes 2, 3, 4, 5, or 6,
• q denotes 1, 2, 3, 4 or 5,
• and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.